A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
List view / Grid view
hepatocellular carcinoma (HCC)
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.